NEW YORK, March 23, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage
biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced
that Herriot Tabuteau, M.D., Axsome’s Chief Executive Officer, will present a corporate overview at the 16th Annual
Needham Healthcare Conference on April 5, 2017 at 8:40 AM Eastern Time. The conference will be held at The Westin NY Grand Central
Hotel in New York, NY.
A live webcast and archive of the event can be viewed on the Company's website at www.axsome.com.
About Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel therapies for the management of central
nervous system (CNS) disorders for which there are limited treatment options. Axsome’s product candidate portfolio includes two
late-stage candidates, AXS-05 and AXS-02. AXS-05 is currently in a Phase 3 trial in treatment resistant depression (TRD), and a
Phase 2/3 trial in agitation in patients with Alzheimer’s disease (AD) is planned. AXS-02 is currently in Phase 3 trials in complex
regional pain syndrome (CRPS) and knee osteoarthritis (OA) associated with bone marrow lesions (BMLs) with an additional Phase 3
trial planned in chronic low back pain (CLBP) associated with Modic changes (MCs). AXS-05 and AXS-02 are investigational drug
products not approved by the FDA. For more information, please visit the company website at www.axsome.com. The company may occasionally disseminate material, nonpublic information on the
company website.
Forward Looking Statements
Certain matters discussed in this press release are “forward-looking statements”. We may, in some cases, use terms such as
“predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,”
“might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking
statements. In particular, the Company’s statements regarding trends and potential future results are examples of such
forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the
success, timing and cost of our ongoing clinical trials and anticipated clinical trials for our current product candidates,
including statements regarding the timing of initiation and completion of the trials; the timing of and our ability to obtain and
maintain U.S. Food and Drug Administration or other regulatory authority approval of, or other action with respect to, our product
candidates; the Company’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost
acceptable to the Company, if at all; the successful implementation of the Company’s research and development programs and
collaborations; the success of the Company’s license agreements; the acceptance by the market of the Company’s product candidates,
if approved; and other factors, including general economic conditions and regulatory developments, not within the Company’s
control. The factors discussed herein could cause actual results and developments to be materially different from those expressed
in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company
undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or
circumstance.
Axsome Contact: Mark Jacobson Vice President, Operations Axsome Therapeutics, Inc. 25 Broadway, 9th Floor New York, NY 10004 Tel: 212-332-3243 Email: mjacobson@axsome.com www.axsome.com
